Nektar Therapeutics (BMV:NKTR)

Market Cap	37.05B +1,051.0%
Revenue (ttm)	994.35M -43.9%
Net Income	-2.95B
EPS	-175.09
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5
Average Volume	108
Open	693.50
Previous Close	1,030.00
Day's Range	693.50 - 693.50
52-Week Range	165.00 - 1,135.00
Beta	n/a
RSI	49.14
Earnings Date	Feb 26, 2026

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has col...

• Industry: Pharmaceutical Preparations
• Founded: 1990
• Employees: 61
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: NKTR

Financial Performance

In 2025, Nektar Therapeutics's revenue was $55.23 million, a decrease of -43.89% compared to the previous year's $98.43 million. Losses were -$164.08 million, 37.9% more than in 2024.

Financial numbers in USD